about
The spread, treatment, and prevention of HIV-1: evolution of a global pandemicComprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodiesFrequent intrapatient recombination between human immunodeficiency virus type 1 R5 and X4 envelopes: implications for coreceptor switchCurrent Trends of HIV Recombination WorldwideGenetic architecture of HIV-1 genes circulating in north India & their functional implicationsStructure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivityBroad Antiviral Activity and Crystal Structure of HIV-1 Fusion Inhibitor SifuvirtideSusceptibility of HIV-1 subtypes B', CRF07_BC and CRF01_AE that are predominantly circulating in China to HIV-1 entry inhibitorsHIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine developmentThe role of recombination in the emergence of a complex and dynamic HIV epidemic.Defining epitope coverage requirements for T cell-based HIV vaccines: theoretical considerations and practical applications.Unselected mutations in the human immunodeficiency virus type 1 genome are mostly nonsynonymous and often deleteriousGoing wild: lessons from naturally occurring T-lymphotropic lentivirusesIdentifying dramatic selection shifts in phylogenetic trees.High-resolution molecular epidemiology and evolutionary history of HIV-1 subtypes in Albania.Expression of monocyte markers in HIV-1 infected individuals with or without HIV associated dementia and normal controls in Bangkok Thailand.Genetic analysis of HIV-1 subtypes in Nairobi, Kenya.Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine.Identification of a novel HIV Type 1 circulating recombinant form (CRF65_cpx) composed of CRF01_AE and subtypes B and C in Western Yunnan, China.Retroviral recombination in vivo: viral replication patterns and genetic structure of simian immunodeficiency virus (SIV) populations in rhesus macaques after simultaneous or sequential intravaginal inoculation with SIVmac239Deltavpx/Deltavpr and SIGenetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions.Molecular epidemiology of simian immunodeficiency virus SIVsm in U.S. primate centers unravels the origin of SIVmac and SIVstm.The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates.Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need?High prevalence of neutralizing activity against multiple unrelated human immunodeficiency virus type 1 (HIV-1) subtype B variants in sera from HIV-1 subtype B-infected individuals: evidence for subtype-specific rather than strain-specific neutralizHuman immunodeficiency virus type 1 group m protease in cameroon: genetic diversity and protease inhibitor mutational featuresIn-depth analysis of a heterosexually acquired human immunodeficiency virus type 1 superinfection: evolution, temporal fluctuation, and intercompartment dynamics from the seronegative window period through 30 months postinfection.Identification of a novel HIV-1 second-generation recombinant form (CRF01_AE/CRF07_BC) in Jilin, China.HIV-1 subtypes and differences in heterosexual HIV transmission among HIV-discordant couples in Rakai, Uganda.Characterization of immune responses to capsid protein p24 of human immunodeficiency virus type 1 and implications for detection.Identification and genetic characterization of a novel CRF22_01A1 recombinant form of HIV type 1 in Cameroon.Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccineBiophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor.HIV type 1 pol gene diversity and genotypic antiretroviral drug resistance mutations in Malabo, Equatorial Guinea.Quantification of unintegrated HIV-1 DNA at the single cell level in vivo.Identification and characterization of CRF02_AG, CRF06_cpx, and CRF09_cpx recombinant subtypes in Mali, West Africa.Comprehensive screening for human immunodeficiency virus type 1 subtype-specific CD8 cytotoxic T lymphocytes and definition of degenerate epitopes restricted by HLA-A0207 and -C(W)0304 allelesIntrapatient diversity and its correlation with viral setpoint in human immunodeficiency virus type 1 CRF02_A/G-IbNG infection.Human immunodeficiency virus type 1 recombination: rate, fidelity, and putative hot spots.
P2860
Q22241890-2878EC8B-1AE8-4425-BFF1-0AA71AFB8FE3Q24561905-5731812B-578C-430F-9148-E98B7A29371AQ24672335-78E6A94A-4964-4B90-876F-F3676B602DD7Q26865754-6CA22046-8984-44E4-BBC3-DB36E610CE81Q26866018-4C68DD6C-210E-47EA-B434-15BB34DF8274Q27660384-D782207E-5676-45F0-B699-5F55027422FCQ27676641-A0FACBE0-A2CE-4223-8B86-8FFD19A58D6EQ28477409-FBF0DFC5-B950-4A71-BC76-7F63641DA292Q30355260-0E6D3A78-837F-4F02-8811-23EB8100EC6FQ30387214-FB9CDE41-E30C-42D8-9D5B-C75517F479D4Q30410411-4F40C5C5-8B8B-4C1B-AD69-434A368022EBQ31047702-6ABE6916-4118-4385-88CF-7F0DE4F33968Q31066870-55299BEE-6DBE-4082-BF6F-98A35890BB45Q33272833-68117E26-2B1D-4D36-B0A7-16E7B1D69371Q33312946-35838358-0565-43F3-BA1F-DB02D994E90EQ33314468-8A6FE716-0637-488A-9307-7BC399CC0BE6Q33368620-F66DB9D4-A82C-4178-8E19-B0243424C77BQ33576984-79542ED8-C71C-4352-B36F-7F101EE8B8E6Q33713826-0B28E38C-ECAF-437B-8D4B-E8393179A7BEQ33724189-51DB2181-CA7A-47B3-B118-B76CC905AC00Q33842152-D31647C6-F6A8-47A5-B469-6A768E2CD0ABQ33883813-C3B1F306-489F-47B9-84B2-B79CF0AE6AF0Q33883874-4BED9B3F-F157-46AF-A9C7-2076ECE46AF0Q33884059-DDB1693A-9596-4544-8E3B-FDE3826B3BFBQ33887693-07800D01-2A6A-4178-B8B7-C70F4A919505Q33920519-EA16F4A6-0576-4C4B-9620-5AEF1F38E3F8Q33951471-7FC5D640-8CB7-4EE0-AA79-6F3083F1B601Q33987333-6E144392-F1C9-476D-A386-892D46CDF0E8Q33988106-33930AC5-83A9-4C79-8FCB-6A7590A941F6Q34023818-B3CD83D7-A770-4E95-8AB9-31A20251518FQ34044972-51057A8B-8662-4BB8-982C-7D0219A12B07Q34098161-2F6E7E59-8F75-4C78-91DB-DB3CEBA6B3F3Q34157802-D5C77DB9-E613-4B91-BB73-F4671F558E1BQ34189558-3E9AF978-AA1B-4184-95F8-827D7CD1639FQ34213839-58701DFC-1A8D-4402-9E90-C6453F82EFADQ34264608-9FC34CC7-2497-4101-9DEC-FCC5812BEC03Q34310014-15A08021-EE9F-45BF-A5C5-1B455AE628DFQ34339044-1EE157ED-F612-4551-81EF-CAEF453B0FEBQ34349322-FADD81CB-25F5-47A3-BF7A-17399C60180BQ34355430-12BB798B-10D5-4F36-ABAB-B4F2D018E668
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Understanding the genetic diversity of HIV-1.
@ast
Understanding the genetic diversity of HIV-1.
@en
Understanding the genetic diversity of HIV-1.
@nl
type
label
Understanding the genetic diversity of HIV-1.
@ast
Understanding the genetic diversity of HIV-1.
@en
Understanding the genetic diversity of HIV-1.
@nl
prefLabel
Understanding the genetic diversity of HIV-1.
@ast
Understanding the genetic diversity of HIV-1.
@en
Understanding the genetic diversity of HIV-1.
@nl
P1433
P1476
Understanding the genetic diversity of HIV-1
@en
P2093
McCutchan FE
P304
P407
P478
14 Suppl 3
P577
2000-01-01T00:00:00Z